Akeso's Lung Cancer Drug Shows Quality of Life Gains Over Pembrolizumab
Event summary
- Akeso presented health-related quality of life (HRQoL) data from the Phase III HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC).
- Ivonescimab, Akeso's PD-1/VEGF bispecific antibody, demonstrated a median progression-free survival (PFS) of 11.14 months versus 5.82 months for pembrolizumab.
- The study showed improvements in global health status, physical function, and emotional function in patients treated with ivonescimab, alongside reductions in cough, hemoptysis, and dyspnea.
- Ivonescimab was approved in China in 2025 for first-line treatment of PD-L1-positive NSCLC.
The big picture
Akeso's data highlights the growing importance of patient-reported outcomes (PROs) in oncology drug development, as quality of life increasingly becomes a key factor in treatment decisions. The company's first-in-class bispecific antibody demonstrates a potential shift away from traditional chemotherapy regimens, offering a more targeted and potentially less toxic treatment option for NSCLC patients. This success positions Akeso as a rising competitor in the global lung cancer therapeutics market, which is projected to reach billions in revenue within the next decade.
What we're watching
- Regulatory Approval
- The success of ivonescimab in China, coupled with these positive HRQoL data, will likely accelerate regulatory review timelines in other major markets, but acceptance will depend on a holistic assessment of benefit-risk.
- Market Adoption
- The demonstrated quality of life benefits could be a key differentiator for ivonescimab, potentially driving faster adoption among patients and physicians, but will require effective communication and patient education.
- Competitive Landscape
- Akeso's success will put pressure on other biopharmaceutical companies developing bispecific antibodies and other novel therapies for NSCLC, potentially leading to increased competition and pricing pressures.
Related topics